Eli Lilly is eyeing an off-ramp for patients to switch from weight loss injections to pills

Photo credit: Karola G via Pexels. Article by Catherine Arnst. Quartz – December 18, 2025.

Although the injectable forms of the popular GLP-1 drugs are more effective, the pills under development are both easier to take and will be cheaper

Eli Lilly reported on Thursday that orforglipron, its experimental pill for obesity, helped a majority of patients in a clinical trial maintain their weight loss after switching from injectable forms of its Zepbound GLP-1 drug and Novo Nordisk’s Wegovy. […]

Click here to view original web page at www.qz.com